Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continuing uptake of new therapies, including Bristol- Myers Squibb/Gilead's Atripla and Johnson & Johnson/Tibotec's Prezista, and the launch of several novel agents, such as Merck's raltegravir and Pfizer's maraviroc, will drive near-term expansion of the HIV market.
According to the new Pharmacor report Emerging HIV Therapies, Atripla will address the significant need for a more-convenient therapy, while the efficacy of Prezista, raltegravir, and maraviroc will benefit highly treatment- experienced patients. The report, which contains insights from detailed thought-leading clinician interviews regarding novel drug targets and treatment approaches complemented by the results of a survey involving more than 140 research scientists, finds that a broad range of novel antiretrovirals, vaccines, microbicides, and gene-based therapies are under investigation for HIV.
The report also finds that, despite the tremendous success of Bristol- Myers Squibb's Sustiva, a non-nucleoside reverse transcriptase inhibitor (NNRTI), as a first-line agent, physicians interviewed believe the drug's safety profile leaves it vulnerable to competition for first-line treatment of HIV.
"Many thought leaders believe that a novel NNRTI or an agent from another class with the efficacy and convenience of Sustiva-but with an improved safety profile-would stand a strong chance of competing with Sustiva as a first-line therapy," said Sylvia Eash, Ph.D., analyst at Decision Resources, Inc.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/